Chronic obstructive pulmonary disease
Conditions
Interventions
A 6-minute walking test will be performed using a movable nasal high flow (AIRVO3TM)
Sponsors
Fukahori Susumu
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1: Individuals aged 40 years or older at the time of consent (irrespective of gender) 2: Respiratory function test results indicating a FEV1/FVC of less than 70% and 30%<=%FEV1 < 80% *Test results obtained up to 3 months prior to the screening date are acceptable 3: Individuals who do not require oxygen administration in their daily activities 4: Individuals who have received a comprehensive explanation of this study and provided voluntary consent with full comprehension
Exclusion criteria
Exclusion criteria: 1 Individuals who have been prescribed home oxygen therapy 2 Individuals experiencing significant impairment in daily functioning due to severe or comorbid conditions 3 Individuals unable to complete the 6-minute walking test due to ambulatory disorders or pain that impedes locomotion 4 Individuals with nasal obstruction 5 Other patients deemed unsuitable as study participants by the principal investigator
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 6-minute walk test results (walking distance) | — |
Secondary
| Measure | Time frame |
|---|---|
| SpO2 during 6-minute walk test, Difference in transcutaneous pCO2, respiratory rate, and modified Borg scale before and after 6-minute walk test Recovery time Distance walked before the first break Time from the initiation of the 6-minute walk to the occurrence of the event, which is defined as the point at which SpO2 reaches 90%, transcutaneous pCO2 45 mmHg, and respiratory rate 22 breaths/min during the 6-minute walk. Subjective symptoms reported by study participants and their opinions regarding device utilization | — |
Contacts
Public ContactSusumu Fukahori
Nagasaki University Hospital
Outcome results
None listed